Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
osteoporosis 25 endocrinologydiseases
strontium ranelate 1 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
strontium ranelate 3351 replacement therapy, selective estrogen receptor modulators, recombinant human parathyroid hormone and strontium ranelate are currently available on the market [[7]]. The common outcomes are osteoporotic fractures [[8], [9]],
Select Disease Character Offset Disease Term Instance
osteoporosis 94 Title: BMC Complementary and Alternative MedicineQianggu capsule for the treatment of primary osteoporosis : evidence from a Chinese patent medicineXu WeiAili XuHao ShenYanming XiePublication date (epub): 2/2017Publication
osteoporosis 406 /2017AbstractBackgroundQianggu Capsule, a Chinese patent medicine, has been widely applied in the clinical practice of primary osteoporosis (POP) in recent years. This study aims to summarize the effectiveness and safety of Qianggu Capsule
osteoporosis 1415 (MD = 0.04 g/cm2; 95% CI: 0.03–0.06; P < 0.001). Meta-analysis exhibited a significant anti osteoporosis effect of Qianggu Capsule on femoral neck BMD (MD = 0.03 g/cm2; 95% CI: 0.01–0.05; P = 0.003)
osteoporosis 2096 included studies, the conclusions should be treated with caution for future research.BackgroundPrimary osteoporosis (POP) is one of the most common chronic conditions, and affects both old men and postmenopausal women
osteoporosis 2445 about 202.43 million people aged 60 years and older at the end of 2013, which faces higher risk of osteoporosis -related fractures [[4]]. From 2002 to 2006, the rates of hip fracture over age 50 years have increased
osteoporosis 3182 are available to treat POP, but pharmacological treatments still plays the dominant role. Major anti osteoporosis agents including bisphosphonates, denosumab, hormone replacement therapy, selective estrogen receptor
osteoporosis 3652 assessment [[12]], quality of life [[13]], and adverse event or adverse drug reaction mainly from anti osteoporosis drugs [[14]]. In some cases, POP patients can benefit from drug therapy optimization and combination
osteoporosis 4057 Suboptimal adherence to therapy may partially be due to adverse effects of long-term conventional anti osteoporosis drugs, such as bisphosphonates [[17], [18]]. Hence, there is a requirement for long-term treatment to
osteoporosis 4412 increased the awareness of the problem and have improved our understanding of the prevention and control of osteoporosis . In China, herbal fufang and single Chinese herb have been widely used for the treatment of POP [[20]–[22]].Qianggu
osteoporosis 5682 number of clinical studies reported the effect of Qianggu Capsule and Qianggu Capsule combined with anti osteoporosis drugs. Therefore, this systematic review provides an evidence of Qianggu Capsule for the management
osteoporosis 6535 studies and key review articles, and from the files of content experts.The search terms included “ osteoporosis ”, “primary osteoporosis”, “senile osteoporosis”, “postmenopausal osteoporosis”, “qianggu
osteoporosis 6563 articles, and from the files of content experts.The search terms included “osteoporosis”, “primary osteoporosis ”, “senile osteoporosis”, “postmenopausal osteoporosis”, “qianggu capsule”, “qiang gu
osteoporosis 6590 content experts.The search terms included “osteoporosis”, “primary osteoporosis”, “senile osteoporosis ”, “postmenopausal osteoporosis”, “qianggu capsule”, “qiang gu capsule” and “Gusuibu”.
osteoporosis 6625 included “osteoporosis”, “primary osteoporosis”, “senile osteoporosis”, “postmenopausal osteoporosis ”, “qianggu capsule”, “qiang gu capsule” and “Gusuibu”. Search terms used for PubMed were
osteoporosis 6754 capsule”, “qiang gu capsule” and “Gusuibu”. Search terms used for PubMed were as follows: ( osteoporosis OR primary osteoporosis OR senile osteoporosis OR postmenopausal osteoporosis) AND (qianggu capsule
osteoporosis 6778 capsule” and “Gusuibu”. Search terms used for PubMed were as follows: (osteoporosis OR primary osteoporosis OR senile osteoporosis OR postmenopausal osteoporosis) AND (qianggu capsule OR qiang gu capsule OR Gusuibu).Types
osteoporosis 6801 “Gusuibu”. Search terms used for PubMed were as follows: (osteoporosis OR primary osteoporosis OR senile osteoporosis OR postmenopausal osteoporosis) AND (qianggu capsule OR qiang gu capsule OR Gusuibu).Types of studiesAll
osteoporosis 6832 PubMed were as follows: (osteoporosis OR primary osteoporosis OR senile osteoporosis OR postmenopausal osteoporosis ) AND (qianggu capsule OR qiang gu capsule OR Gusuibu).Types of studiesAll completed randomised controlled
osteoporosis 8409 duration of treatment was required to be at least 3 months.Types of outcomesThe primary outcome was osteoporosis -related fractures. The secondary outcomes analyzed in this review were BMD values, pain scores, quality
osteoporosis 10812 three-group design study that had two treatment groups of Qianggu Capsule and Qianggu Capsule plus anti osteoporosis drugs, the two comparisons were split in the meta-analysis. Heterogeneity was assessed by means of I2
osteoporosis 12791 articles, 806 participants were enrolled in the review and depicted in Table 1. Eight trials used Chinese osteoporosis diagnostic criteria [[38], [40]–[42], [44]–[47]]. Two trials were also included because BMD was
osteoporosis 18558 interventionsAll the included studies compared Qianggu Capsule practised alone or combined with anti osteoporosis drugs. According to the different intervention and control program, the interventions could be divided
osteoporosis 20510 P = 0.09, Fig. 5) between the groups [[42], [43], [45]]. Meta-analysis indicated a significant anti osteoporosis effect of Qianggu Capsule on femoral neck BMD (MD = 0.03 g/cm2; 95% CI: 0.01–0.05; P = 0.003,
osteoporosis 24449 used to treat bone metabolic diseases and known for anti-osteoporotic drugs [[48]–[51]]. The anti- osteoporosis effect of Rhizoma Drynariae and its extracts have attracted world-wide attention [[52], [53]]. Our systematic
osteoporosis 24658 Our systematic review is to assess the efficacy and safety of Qianggu Capsule (Rhizoma Drynariae) in osteoporosis therapy. The results of meta-analysis suggested that Qianggu Capsule plus Caltrate D was more effective

You must be authorized to submit a review.